Physician profile
Jordan Vogt
NPI 1770004202
$11,989.72
in general payments reported to CMS, 2019-2025
33 companies · $19.84 in 2025
The $19.84 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,887 · 2020: $1,221 · 2021: $2,631 · 2022: $595 · 2023: $1,229 · 2024: $1,408 · 2025: $19.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,323 · Long Term Medical Supply Or Device Loan: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,322.96 |
| Long Term Medical Supply Or Device Loan | $333.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $4,458.00 | 2019-2024 | Variax, Allofiber, Anchorage |
| Alpha Orthopedic Systems | $3,354.85 | 2019-2020 | |
| Legacy Ortho LLC | $1,200.00 | 2021 | |
| Smith+Nephew, INC. | $919.26 | 2020-2025 | Grafix Pl, Stravix, Stravix Pl |
| Integra Lifesciences Corporation | $390.36 | 2023-2024 | Acell, Integra, Tenoglide |
| Organogenesis INC. | $275.39 | 2019-2023 | Puraply |
| Abbvie INC. | $154.24 | 2022-2024 | Dalvance |
| Celularity INC. | $112.00 | 2019 | |
| Horizon Therapeutics Plc | $108.10 | 2019 | |
| Polynovo North America LLC | $107.28 | 2024 | Novosorb Btm |
| Misonix INC | $106.17 | 2019 | |
| Melinta Therapeutics, LLC | $98.83 | 2021 | |
| Zimmer Biomet Holdings, INC. | $96.31 | 2019-2021 | |
| Depuy Synthes Sales INC. | $79.35 | 2023-2024 | Minibunion, Na, Motoband |
| Paratek Pharmaceuticals, INC. | $62.74 | 2023 | Nuzyra |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $61.35 | 2019-2023 | Physio-Stim |
| Arthrosurface Incorporated | $58.88 | 2019 | |
| Mimedx Group, INC. | $54.78 | 2024 | |
| Bioventus LLC | $34.62 | 2023-2024 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| Nuvasive, INC. | $30.96 | 2019 | |
| Ethicon US, LLC | $25.12 | 2020 | |
| Convatec INC. | $23.91 | 2023 | |
| Sebela Pharmaceuticals INC. | $20.53 | 2023 | Naftin, Pramosone |
| Pacira Pharmaceuticals Incorporated | $19.85 | 2020 | |
| Baxter Healthcare | $19.66 | 2019 | |
| Averitas Pharma INC. | $19.11 | 2023 | Qutenza |
| Medtronic, INC. | $17.61 | 2021 | |
| Acera Surgical, INC. | $15.36 | 2023 | Restrata Wound Matrix |
| Kerecis Limited | $14.99 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Ibsa Pharma INC. | $14.01 | 2023 | Tirosint, Licart |
| Nevro Corp. | $13.42 | 2023 | Senza |
| Checkpoint Surgical, INC | $11.48 | 2023 | Checkpoint Stimulators |
| Paragon 28, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Vogt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.